Severe Nervous System Complications After Botulinum Type A Therapy: Three Case Reports With Reviews of FDA‐Reported Nervous System Adverse Effects

@article{Hristova2012SevereNS,
  title={Severe Nervous System Complications After Botulinum Type A Therapy: Three Case Reports With Reviews of FDA‐Reported Nervous System Adverse Effects},
  author={A. Hristova and L. Joseph and S. Sathe and J. Wade},
  journal={PM\&R},
  year={2012},
  volume={4}
}
The short-term safety of botulinum toxin type A (BoNT/A) has been established in numerous double-blind trials, but as many authors have pointed out, long-term drug safety is an unresolved issue [1-3]. We report 3 cases of central nervous system complications with encephalitic clinical features that occurred shortly after treatment of focal dystonia with BoNT/A. The goal of this study is to raise awareness and increase the vigilance of health care providers regarding the possible occurrence of… Expand
Botulinum Toxin Type A injections for pediatric spasticity: Keeping our patients informed and practices safe.
TLDR
Suggestions for content sharing during the consent process are offered to optimize patient understanding about potential adverse events following BoNT-A for pediatric spasticity. Expand
The whole truth about botulinum toxin – a review
TLDR
The aim of this study was to provide an overview of Botox-related side effects and advise potential management and preventive strategies. Expand
Diffusion, spread, and migration of botulinum toxin
TLDR
There is a remarkable paucity of published data on the mechanisms of distribution and its effects on clinical outcomes of Botulinum toxin, and the primary aim of this article is to critically review the available experimental and clinical literature and place it in the practical context. Expand

References

SHOWING 1-10 OF 82 REFERENCES
[Frequency of side effects after botulinum toxin A injections in neurology, rehabilitation and gastroenterology].
TLDR
Therapy with BTX-A is a very safe procedure, especially when compared with high rate of effectiveness of injections, the side effects are transient, mostly local and completely reversible. Expand
[A case report of acute polyradiculoneuritis developing after multiple injections of botulinum toxin for cervical dystonia].
TLDR
A 68-year-old man receiving four times of injection of botulinum toxin type A for cervical dystonia developed acute polyradiculoneuritis 10 weeks after the final injection, suggesting that botulinu toxin therapy is involved in the pathogenesis in this case. Expand
Generalised botulism-like syndrome after intramuscular injections of botulinum toxin type A: a report of two cases.
TLDR
Two patients in whom treatment with therapeutic doses of BT/A resulted in a generalised muscle weakness with widespread EMG abnormalities which were typical of botulism are reported. Expand
Botulinum-A toxin in the treatment of craniocervical muscle spasms: short- and long-term, local and systemic effects.
TLDR
Until further studies on the long-term distant complications of botulinum toxin are available, it is recommended that patients receive as few life-time doses of toxin as possible, consistent with adequate management of their spasms. Expand
Safety of botulinum toxin type A among children with spasticity secondary to cerebral palsy: a systematic review of randomized clinical trials
TLDR
Botulinum toxin type A has a good safety profile during the first months of use, however the occurrence of adverse events is more frequent among children with cerebral palsy than individuals with other conditions, and additional study is required to clarify the causal relation. Expand
Clinical features of types A and B food-borne botulism.
TLDR
Although the case-fatality ratio was not significantly greater, patients with type A disease saw a physician earlier in the course of illness, were more likely to need ventilatory support, and were hospitalized longer. Expand
Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases.
TLDR
Serious AEs were more likely to be reported for therapeutic than for cosmetic use, which may be related to higher doses, complicated underlying diseases, or both. Expand
Generalised muscular weakness after botulinum toxin injections for dystonia: a report of three cases
TLDR
Three patients are reported on who developed transient generalised weakness after receiving therapeutic doses of botulinum toxin for cervical dystonia and symptomatic hemidystonia, most likely presynaptic inhibition due to systemic spread of the toxin. Expand
Polyradiculoneuritis after botulinum toxin therapy for cervical dystonia.
TLDR
A 40-year-old man with cervical dystonia developed an acute inflammatory demyelinating polyradiculoneuritis after botulinum toxin type A treatment, and the clinical temporal profile suggests a pathogenic relationship. Expand
AN HISTOLOGICAL STUDY OF THE CENTRAL NERVOUS SYSTEM IN EXPERIMENTAL BOTULINUS POISONING
TLDR
Recent physiological experiments afford evidence that the peculiar and distressing symptoms of botulinus poisoning may be explained upon the hypothesis that the real site of action of the toxin is upon nerve terminals and that the paralytic features are not of central origin, as was formerly supposed. Expand
...
1
2
3
4
5
...